Our study provides a proof-of-concept CCRT prediction biomarker, i.e., low SOX17 immunohistochemical stain in pre-treatment endoscopic biopsies that can predict CCRT response in ESCC patients with intrinsic resistance. This evidence concerns the gene SOX17 and esophageal squamous cell carcinoma.